Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results

Autor: Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, SN, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::4a7c0f87dcd767b2e381f923b54e63c9
https://ora.ox.ac.uk/objects/uuid:5918f1de-82f5-42ed-977c-20b1f662d3df

Risk prediction for clonal cytopenia: multicenter real-world evidence.

Autor: Xie Z; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.; Division of Hematology, Mayo Clinic, Rochester, MN., Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Al Ali N; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Regelson A; Department of Biostatistics, Mayo Clinic, Rochester, MN., Geyer S; Department of Biostatistics, Mayo Clinic, Rochester, MN., Patel A; Leukemia Program, University of Chicago Comprehensive Cancer Center, Chicago, IL., Saygin C; Leukemia Program, University of Chicago Comprehensive Cancer Center, Chicago, IL., Zeidan AM; Division of Hematology, Departments of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT., Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Mendez L; Division of Hematology, Departments of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT., Kishtagari A; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Zeidner JF; Division of Hematology, The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Coombs CC; Division of Hematology, The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Madanat YF; Division of Hematology, The University of Texas Southwestern Medical Center, Dallas, TX., Chung S; Division of Hematology, The University of Texas Southwestern Medical Center, Dallas, TX., Badar T; Division of Hematology, Mayo Clinic Florida, Jacksonville, FL., Foran J; Division of Hematology, Mayo Clinic Florida, Jacksonville, FL., Desai P; Division of Hematology and Oncology, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY., Tsai C; Division of Hematology and Oncology, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY., Griffiths EA; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Al Malki MM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Amanam I; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Lai C; Division of Hematology/Oncology, University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA., Deeg HJ; Division of Hematology, Fred Hutchinson Cancer Center, Seattle, WA., Ades L; Department of Hematology, Hospital Saint-Louis, Paris, France., Arana Yi C; Division of Hematology, Mayo Clinic Arizona, Phoenix, AZ., Osman AEG; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, The University of Utah Salt Lake City, Salt Lake City, UT., Dinner S; Division of Hematology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Abaza Y; Division of Hematology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Taylor J; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Chandhok N; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Soong D; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Brunner AM; Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Carraway HE; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program Cleveland, Cleveland, OH., Singh A; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program Cleveland, Cleveland, OH., Elena C; Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy., Ferrari J; Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Gallì A; Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy., Pozzi S; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Patnaik MM; Division of Hematology, Mayo Clinic, Rochester, MN., Malcovati L; Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy., Savona MR; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Al-Kali A; Division of Hematology, Mayo Clinic, Rochester, MN.

Publikováno v: Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 2033-2044.

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Autor: Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Huang Y; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Welkie RL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lin TL; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Archer KJ; Division of Biostatistics, The Ohio State University, Columbus, OH., Patel PA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Baer MR; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Duong VH; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Stock W; Department of Medicine, The University of Chicago, Chicago, IL., Odenike O; Department of Medicine, The University of Chicago, Chicago, IL., Redner RL; Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA., Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA., Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA., Foran JM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL., Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA., Curran EK; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Koenig KL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Chen T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Martycz M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Stefanos M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Marcus SG; Leukemia & Lymphoma Society, Rye Brook, NY., Rosenberg L; Leukemia & Lymphoma Society, Rye Brook, NY., Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Burd A; Leukemia & Lymphoma Society, Rye Brook, NY., Yocum AO; Leukemia & Lymphoma Society, Rye Brook, NY., Borate UM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Byrd JC; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Publikováno v: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5297-5305.

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.

Autor: Bewersdorf JP; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. jan.bewersdorf@yale.edu.; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. jan.bewersdorf@yale.edu., Shallis RM; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Park S; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Ramaswamy R; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Roe CE; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.; Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, TN, USA., Irish JM; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.; Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, TN, USA., Caldwell A; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Wei W; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Yacoub A; The Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), The University of Kansas Cancer Center, Westwood, KS, USA., Madanat YF; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Zeidner JF; Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Altman JK; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA., Odenike O; University of Chicago, Chicago, IL, USA., Yerrabothala S; Hitchcock Cancer Center, Dartmouth University, Lebanon, NH, USA., Kovacsovics T; University of Utah, Huntsman Cancer Center, Salt Lake City, UT, USA., Podoltsev NA; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Halene S; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Piekarz R; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Gore SD; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Kim TK; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. tae.k.kim@vumc.org.; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.; Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, TN, USA. tae.k.kim@vumc.org., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. amer.zeidan@yale.edu.; Hematology Section, Department of Internal Medicine, Yale School of Medicine, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA. amer.zeidan@yale.edu.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 105-116. Date of Electronic Publication: 2023 Dec 01.

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Autor: Shallis RM; Department of Internal Medicine, Section of Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA., Daver N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Altman JK; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Komrokji RS; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Pollyea DA; Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA., Badar T; Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA., Bewersdorf JP; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bhatt VR; Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE, USA., de Botton S; Gustave Roussy Cancer Center, Villejuif, France., de la Fuente Burguera A; MD Anderson Cancer Center, Madrid, Spain., Carraway HE; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Desai P; Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA., Dillon R; Department of Medical and Molecular Genetics, King's College, London, UK., Duployez N; Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France., El Chaer F; Department of Medicine, Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA., Fathi AT; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Gojo I; Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Jonas BA; Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis, Davis, CA, USA., Konopleva M; Montefiore Einstein Cancer Center & Albert Einstein College of Medicine, New York, NY, USA., Lin TL; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, USA., Mannis GN; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA., Mascarenhas J; Tisch Cancer Institute, Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Michaelis LC; Division of Hematology and Oncology, Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Montesinos P; Hospital Universitari I Politecnic La Fe, Valencia, Spain., Pozdnyakova O; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Pratz KW; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Schuh AC; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada., Sekeres MA; Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL, USA., Smith CC; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Stahl M; Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Subklewe M; Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany., Uy GL; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA., Voso MT; Department of Biomedicine and Prevention, Tor Vergata University, and Neuro-Oncohematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Santa Lucia, Rome, Italy., Walter RB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Zeidner JF; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Žučenka A; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania and Institute of Clinical Medicine, Vilnius, Lithuania., Zeidan AM; Department of Internal Medicine, Section of Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2023 Sep; Vol. 10 (9), pp. e767-e776. Date of Electronic Publication: 2023 Aug 09.